Answers are grounded in this paper and cite their sources.
INTRODUCTION: Migraine therapy has advanced in recent years, particularly with the emergence of calcitonin gene-related peptide (CGRP)-targeting drugs. However, acute treatment still faces limitations, especially in patients who are unresponsive to or unable to take triptans or gepants. Transient receptor potential melastatin 8 (TRPM8) is a polymodal-gated, nonselective cation channel that represents a promising target for the treatment of migraine supported by genetic, preclinical and clinical evidence. AREAS COVERED: This review covers the evidence supporting an important role for TRPM8 in the pathophysiology of migraine and provides a detailed synopsis of the preclinical, pharmacodynamic and pharmacokinetic profiles of potential TRPM8-interacting compounds in clinical development for the treatment of migraine. PubMed and ClinicalTrials.gov were searched to August 2026 for TRPM8 and migraine, supplemented by 2026 congress abstracts and company disclosures. EXPERT OPINION: TRPM8 channel blockade has a mechanistically distinct approach from current therapeutics. A proof-of-concept and dose range finding Phase 2 study with elismetrep, a novel, oral TRPM8 blocker, provides supportive, although not definitive, evidence for TRPM8 blockers in migraine. Although the primary endpoint of 2-hour pain freedom was not statistically significant, numerically greater effects at 20 mg and nominally significant secondary-endpoint findings support further development.
No takes yet. Share an insight, caveat, or question.
Pellesi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: